|
The following was reported to gore on (b)(6) 2025 from the imedidata study database: on (b)(6) 2025, this 62-year-old male patient underwent endovascular treatment for an aortoiliac aneurysm.The patient was treated with a gore® excluder® aaa trunk ipsilateral leg endoprosthesis, gore® excluder® aaa endoprosthesis devices and gore® excluder® branch endoprosthesis devices.There was successful access, delivery and accurate deployment of the devices to the intended location and successful retrieval of the delivery systems.The patient was discharged home on (b)(6) 2025.It was reported that the patient had intraoperative bleeding related to treatment/procedure.This led to transfusion.
|
|
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H6: a review of the manufacturing records for the device verified that the lot met all pre-release specifications.As gore was unable to determine which device/device component is involved in this reportable adverse event, the following additional device will be identified in this report: catalog #dsf1633, serial #(b)(6), udi (b)(4) / catalog #dsf1633, serial #(b)(6), udi (b)(4).W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
The following was reported to gore from the imedidata study database: on (b)(6) 2025, this 62-year-old male patient underwent endovascular treatment for an aortoiliac aneurysm.The patient was treated with a gore® excluder® aaa trunk ipsilateral leg endoprosthesis, gore® excluder® aaa endoprosthesis devices and gore® excluder® branch endoprosthesis devices.There was successful access, delivery and accurate deployment of the devices to the intended location and successful retrieval of the delivery systems.It was reported that the patient had a bleeding at the left femoral artery access site related to treatment/procedure.This led to transfusion.The patient was discharged home on (b)(6) 2025.
|